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Taxanes are standard therapy in clinical practice for metastatic breast cancer (BC), however, 
primary or acquired chemoresistance are a common cause of mortality. BC patient-derived 40 
xenografts (PDX) are powerful tools for the study of cancer biology and drug treatment 
response. Specific DNA-methylation patterns have been associated to different BC subtypes 
but its association with chemoresistance remains unstudied. Aiming to elucidate docetaxel-
resistance mechanisms, we perform genome-wide DNA-methylation in BC PDX models, 
including luminal and triple-negative BC (TNBC) models sensitive to docetaxel, their 
matched models after emergence of chemoresistance and residual disease after short term 
docetaxel treatment. We found that DNA-methylation patterns from BC PDX models 
maintain the subtype-specific methylation patterns of clinical samples. Two main DNA-
methylation clusters were found in TNBC PDX and remain stable during the emergence of 
docetaxel resistance; however, some genes/pathways were differentially methylated 50 
according to docetaxel response. A DNA-methylation signature of resistance able to 
segregate TNBC chemotherapy response was identified. Transcriptomic profiling of selected 
sensitive/resistant pairs and integrative analysis with methylation data demonstrated 
correlation between some differentially methylated and expressed genes in docetaxel-
resistant TNBC PDX models. Multiple gene expression changes were found after the 
emergence of docetaxel resistance in TNBC. DNA-methylation and transcriptional changes 
identified between docetaxel-sensitive and resistant TNBC PDX models or residual disease 
may have predictive value for chemotherapy response in TNBC. 
Implications 
Subtype-specific DNA-methylation patterns are maintained in BC PDX models. While no 60 
global methylation changes were found, we uncovered differentially DNA-methylated and 
expressed genes/pathways associated to the emergence of docetaxel resistance in TNBC.
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Combination of different chemotherapy regimens, together with targeted therapies are used 
for the treatment of distinct breast cancer subtypes (1). Despite initial responses, relapses or 
metastatic disease usually become treatment resistant in breast cancer patients (2), and 
account for the main cause of death in these patients: chemoresistant breast cancer has a 5-
year survival rate of around 25% (2). Triple-negative breast cancer (TNBC), the most 
heterogeneous and aggressive subtype of breast cancer, has higher rates of response to 
neoadjuvant chemotherapy than other breast cancer subtypes, but resistance rapidly emerges 70 
(3). Taxanes are considered among the most active classes of compounds against TNBC and 
metastatic breast cancer (4). Docetaxel, a taxane chemotherapeutic agent used broadly for 
treatment of different cancer types, acts by binding to microtubules and avoiding tubulin 
subunits depolimerization, inducing cell cycle arrest, apoptosis and cell death (5). Several 
mechanisms have been suggested to confer docetaxel resistance for different cancer types, as 
prostate (6), gastric (7) and ovarian (8). In breast cancer, the best known chemoresistance 
mechanism is the modulation of drug efflux proteins (9). However, small molecule inhibitors 
of drug efflux proteins have being tested in patients with limited clinical success (9). Other 
molecular mechanisms of docetaxel resistance implying gene expression deregulation and 
epigenetic mechanisms have been proposed (10). Most studies have been performed in vitro 80 
using breast cancer cell lines (BCCLs), with limited predictive value in the clinics (11,12), or 
focusing on gene expression signatures of patient populations, where heterogeneity, 
particularly in TNBC is a major concern (13,14). Further insights to clarify the emergence of 
docetaxel resistance are urgently required. One important limitation is the availability of 
paired clinical samples before and after acquisition of resistance.  
DNA-methylation-specific alterations are known hallmarks of human cancer (15,16). Several 
studies have also identified DNA-methylation signatures that can distinguish between breast 
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cancer subtypes (17,18), and others that may be predictive of treatment response (19,20). 
DNA-methylation changes can contribute to cancer development through inactivation of 
tumor suppressor genes (BRCA1 and others) and, conversely, through activation of 90 
oncogenes (21). DNA-methylation has been also uncovered as an important clinical marker 
of drug response and resistance in breast cancer in some contexts (21,22). 
Patient-derived xenograft (PDX) models have been proposed as a preferred tool for 
conducting basic and translational preclinical research, being biologically closer to patient 
tumors than cancer cell lines (11,12). Breast cancer PDX models maintain not only 
histopathological features from human tumors but also retain main genomic, transcriptomic 
and proteomic profiles and drug response (11,17). However, methylation patterns of breast 
cancer PDX models and their correlation with human breast tumors remain understudied. 
Multiple investigations support the relevance of PDX models as powerful preclinical tools for 
the study of drug resistance, but it is necessary to determine whether breast cancer 100 
methylation patterns are represented and maintained in PDX models to establish their 
suitability for preclinical methylation studies. 
We have generated a panel of breast cancer PDX models comprising all histopathological 
subtypes (23). Mimicking the clinical scenario, TNBC PDX models respond to docetaxel 
while luminal PDX models proved to be resistant. However, after continuous in vivo 
exposure to docetaxel, initially sensitive TNBC PDX models become resistant (23). These 
paired sensitive and resistant TNBC PDX models, as well as the residual disease from 
sensitive TNBC PDX models, solve the gap between in vitro results and clinical samples and 
constitute powerful tools for the study of docetaxel chemoresistance. 
We hypothesize that DNA-methylation and transcriptional changes contribute to the 110 
emergence of chemoresistance to docetaxel in TNBC patients. Here we performed genome-
wide DNA-methylation in a panel of 12 breast cancer PDX models, corresponding residual 
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disease after docetaxel treatment for the 9 TNBC, and paired chemoresistant-derived TNBC 
PDX tumors generated. Transcriptional profiles for selected docetaxel-sensitive/resistant 
TNBC PDX pairs were also obtained. We demonstrated that human breast cancer 
methylation patterns are conserved in breast cancer PDX models and can discriminate 
different subgroups within the heterogeneous TNBC subtype. Although global methylation is 
preserved during the emergence of chemoresistance, some gene-specific methylation changes 
are detected. Transcriptionally, multiple genes were differentially expressed between paired 
sensitive and resistant TNBC PDX tumors. Differentially methylated/expressed genes were 120 
associated to specific pathways. Similar pathways were found between methylation and 
expression analysis, suggesting that some gene expression changes are controlled by 
methylation during emergence of chemoresistance to docetaxel in TNBC PDX tumors, 
although most of the transcriptional changes identified were not related to methylation. 
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Materials and methods 
Patient Characteristics and Generation of PDX 
All human samples were obtained following institutional guidelines. Written informed 
consent for PDX generation and whole exome sequencing was obtained from all subjects and 
the study received approval from the corresponding institutional Ethics Committee in 130 
accordance with the Declaration of Helsinki. All research involving animals was performed 
in compliance with protocols approved by the Institutional Committees on Animal Care and 
adhering to European Union and international regulations. PDX models were generated as 
previously described (23). IDB PDX (TNBC IDB-01, IDB-02, IDB-09, luminal IDB-03 and 
IDB-04 and the HER2+ IDB-05), BCM PDX (BCM-4664, BCM-9161) and HCI-001 PDX 
models were generated by orthotopic transplantation of human fresh tumoral tissue or 
injection of metastatic cancer cells isolated from pleural effusions into the cleared mammary 
fat pad of immunodeficient mice, as described previously (23–25). VHIO models (VHIO-98, 
VHIO-127 and VHIO-270) were generated by subcutaneous implantation of primary tumor 
pieces or metastasis on the back of Foxn1
nu
 mice as described in (26). VHIO, BCM and HCI 140 
PDX models were implanted in the intact fact pad of NOD.CB17-Prkdc
scid
/J mice of our 
animal facility where short term treatments with docetaxel (Residual Disease) and generation 
of resistant variants (IDB-09R, VHIO-98R and VHIO-127R) was performed as described 
(23). DNA-methylation profiles from paired sensitive and resistant TNBC PDX and/or 
residual disease previously described (23,27) and human samples of origin (when available) 
were obtained. All resistant TNBC PDX models used in this study were maintained under in 
vivo selective drug pressure and they were completely resistant [passage 3 of resistance for all 
model except VHIO-98R (passage 4 of resistance)]. Residual disease and resistant TNBC 
PDX tumors were collected between four and seven days after the last docetaxel treatment. 
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Also, it is important to mention that IDB-02S model was partially sensitive, but from now on 150 
will be considered as sensitive to facilitate nomenclature. 
DNA Extraction and RNAse Treatment 
Total DNA from tissue was prepared with in house lysis buffer (100mM NaCl, 10mM Tris-
Cl pH 8, 25mM EDTA). Frozen tumor tissues were fractionated using the POLYTRON® 
system PT 1200 E (Kinematica) and incubated 12-16 hours with 0.25% SDS (Invitrogen, 
24730020), 0.25 mg/ml Proteinase K (Sigma Aldrich, P4850) and RNAse A (Sigma Aldrich, 
R5503) at 55ºC in a termal block. For DNA purification, the homogenized sample was 
transferred to a phase lock gel heavy tube (VWR, 713-2538). Two steps of removal of 
proteins from nucleic acids using Phenol:Chloroform:Isoamyl Alcohol 25:24:1 (Sigma 
Aldrich, P3803) and three steps of nucleic acid washing with chloroform (VWR, 160 
1024311000) were performed, centrifuging each time at 1500G during 5 minutes. After last 
spinning, remaining volume containing DNA was recovered and transferred to a solution 
containing 2.5x absolute ethanol (Merck Millipore, 1009832500) and 30 mM of sodium 
acetate pH 5.2 (Sigma Aldrich, S2889), mix and centrifuge at maximum for 5 minutes. Wash 
two times with 70% ethanol centrifuging at maximum for 5 minutes. Finally, resuspension in 
TE buffer (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0) or ultrapure water (MilliQ 
purification system) was performed. All DNA samples were quantified by the fluorometric 
method (Quant-iT PicoGreen dsDNA Assay, Life Technologies, CA, USA), and assessed for 
purity by NanoDrop-1000 Spectrophotometer (Thermo Scientific, MA, USA) 260/280 and 
260/230 ratio measurements. DNA integrity of samples was checked by electrophoresis in an 170 
agarose gel. 
 
Bisulfite Conversion and Genome-Wide DNA-methylation Microarray 
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Five hundred nanograms of purified genomic DNA were treated with sodium bisulfite using 
the EZ DNA-methylation kit (Zymo Research, CA, USA). The incubation profile was 16 
cycles at 95°C for 30 s, 50°C for 60 min and a final holding step at 4°C. 4 μl of bisulfite-
converted DNA (50 ng/ul) were used for hybridization on Infinium Human Methylation 
450K BeadChip, following the Illumina Infinium HD Methylation protocol. This consisted of 
a whole genome amplification step followed by enzymatic end-point fragmentation, 
precipitation and resuspension. The resuspended samples were hybridized on Human 180 
Methylation 450K BeadChips at 48°C for 16 h. Then unhybridized and non-specifically 
hybridized DNAs were washed away, followed by a single nucleotide extension using the 
hybridized bisulfite-treated DNA as a template. The nucleotides incorporated were labeled 
with biotin (ddCTP and ddGTP) and 2,4-dinitrophenol (DNP) (ddATP and ddTTP). After the 
single base extension, repeated rounds of staining were performed with a combination of 
antibodies that differentiated DNP and biotin by fixing them different fluorophores. Finally, 
the BeadChip was washed and protected in order to scan it. 
The Illumina HiScan SQ scanner (Illumina, CA, USA) is a two-color laser (532 nm/660 nm) 
fluorescent scanner with a 0.375 μm spatial resolution capable of exciting the fluorophores 
generated during the staining step of the protocol. The intensities of the images were 190 
extracted and raw IDAT files were processed with Illumina’s GenomeStudio software and 
statistical analysis was done in R with minfi package. The methylation score for each CpG 
was represented as a β-value according to the fluorescent intensity ratio. β-values may take 
any value between 0 (non-methylated) and 1 (completely methylated) and they were used for 
all downstream analyses. All downstream analysis was conducted using the hg19/GRCh37 
human genome assembly. 
Methylation Clustering 
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Confirmation that samples from same donor were properly analysed, was assessed by 
confronting 59 SNP values obtained within the Illumina Infinium Human Methylation 450K 
BeadChip and the Illumina Infinium Human MethylationEPIC BeadChip microarray from the 200 
different samples. Scatter plots of β-values for PDX models and human samples of origin 
were produced to check if there was a degree of difference between the models. Afterwards, 
an analysis of methylation variance, comparing PDX models was applied to β-values 
obtaining the CpGs statistically significant (FDR < 0.01) taking into account a methylation 
difference between at least one of the groups equal or higher to 75%. An unsupervised 
heatmap representation of the PDX models was generated using those CpGs. Organizing the 
values by applying a hierarchical clustering method based on Manhattan distances aggregated 
by Ward’s linkage. An analysis of methylation variance revealed a minimum of 743 CpGs 
differentially methylated CpGs between TNBC vs luminal subtype from TCGA breast cancer 
patients, and then were applied to classify PDX models and breast cancer cell lines (BCCLs). 210 
Data from primary tumor samples were obtained from TCGA data portal 
(https://portal.gdc.cancer.gov/) while data from BCCLs were obtained from (28). DNA-
methylation data from TCGA derives from Illumina Infinium Human Methylation 450K 
BeadChip platform which interrogates approximately 450,000 CpG sites in comparison with 
the EPIC microarray which interrogates 850,000 CpG sites approximately; around 90% of the 
Infinium Human Methylation 450K BeadChip microarray is still found in the Infinium 
MethylationEPIC BeadChip platform. Thus, data was merged to keep around 452,256 CpG 
sites present in both methylation platforms. 
Unsupervised heatmap representation of the PDX models and 100 human mammary gland 
samples (from TCGA) was generated using randomly selected 1% of the CpG sites and 220 
organizing them by applying a hierarchical clustering method based on Manhattan distances 
aggregated by Ward’s linkage. 
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Pyrosequencing assays were designed to analyze and validate the results obtained from the 
array under different scenarios. Sodium bisulfite modification of 1 μg of genomic DNA 
isolated from breast cancer PDX tumors was carried out with the EZ DNA-methylation Kit 
(Zymo Research Corporation) following the manufacturer's protocol. Bisulfite-treated DNA 
was eluted in 30-μL volumes with 2 μL used for each PCR. The set of primers for PCR 
amplification and sequencing were designed with a specific program (PyroMark assay design 
version 2.0.01.15). Primer sequences were designed to hybridize with CpG-free sites to 230 
ensure methylation-independent amplification. PCR was performed with primers biotinylated 
to convert the PCR product to single-stranded DNA templates. We used the Vacuum Prep 
Tool (Biotage) to prepare single-stranded PCR products according to the manufacturer's 
instructions. Pyrosequencing reactions and quantification of methylation were performed in a 
PyroMark Q96 MD version 2.0.6 (QIAGEN). Primers indicated below are in 5’  3’ 
direction. 
Primers 
hSLC25A30 Forward   AGTTTTTATTGGTTTTTGTTAGTATTAGT 
hSLC25A30 Reverse Biotinylated TTCCCCAAATTTCTCTTCCACC 
hSLC25A30 Forward PyroSeq TGATAGTTTTAGATGGGGATA 240 
RNA Extraction and Gene Expression Microarray 
Total RNA from tissue was prepared with Tripure Isolation Reagent (Roche). Frozen tumor 
tissues from sensitive and resistant IDB-01 and IDB-02 TNBC PDX models were 
fractionated using the POLYTRON® system PT 1200 E (Kinematica). Two-hundred-
nanogram aliquots of total RNA were used for the production of fluorescent complementary 
RNA following the Two-Color Microarray-Based Gene Expression Analysis v. 6.5 (Agilent) 
protocol under manufacturer’s instructions. All samples were hybridized to the SurePrint G3 
on July 24, 2019. © 2019 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1541-7786.MCR-19-0040 
12 
 
Human Gene Expression 8 × 60 K microarray (Agilent Technologies). The signal values 
were extracted using the Feature Extraction software (Agilent Technologies). After scanning 
and normalization processes, all the statistical treatment was realized under an R 250 
programming environment using Bioconductor’s package for gene expression analysis: 
Limma, RankProd, Marray, affy, pcaMethods, EMA y RamiGO. 
Differentially expressed genes, after Limma analysis, were represented as a mean-centered 
gene expression graphs using web-based tool Morpheus from Broad Institute (29). 
Correlation between Gene Expression and Methylation  
To study the association between gene expression and DNA-methylation at gene level, data 
derived from both arrays was filtered to obtain the mean methylation value for each gene 
found in the expression array and annotated in the Infinium Human Methylation 450 
BeadChip Array. In the case of methylation, CpG site probes falling on the promoter region 
of the known genes were considered, i.e., TSS1500, TSS200, 5’UTR, and 1st exon. 260 
Methylation beta values of CpG islands were averaged across CpG sites. A Pearson 
correlation test was performed for all the genes in the Expression Array, first correlating the 
genes intra models IDB-01 and IDB-02 and later calculating the correlation within the 
sensitive and resistant samples independently. Density plots were created with the correlation 
values per model or based on the sensitive/resistant conditions. Also, for those genes that 
were previously considered as differentially expressed (logFC >=1.5 and adj.P.Val <=0.05). 
A heatmap with the most differentially expressed genes was generated organizing the mean 
expression values by applying a clustering method based on Manhattan distances, and 
drawing its equivalent mean methylation values with its corresponding gene.  
Statistical analysis and graphical representation were performed with R programming 270 
language (version 3.4 2017-04-21) and limma (version 3.30.13) and ggplot2 libraries. 
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Significant differences between samples/models were assessed using Wilcoxon, Pearson or 
Chi-tests were appropriate with values of p<0.05 considered to be significant. 
Gene Ontology/Pathway Analyses 
To identify functional clusters of genes differentially methylated and/or differentially 
expressed, we performed Functional Annotation Clustering using DAVID (30) on the 
candidate genes obtained from sensitive/resistant pairs and sensitive/residual disease pairs 
comparisons.  
GSEA Analysis 
Gene Set Enrichment Analysis (GSEA) is freely available and is supported by the Broad 280 
Institute website (http://software.broadinstitute.org/gsea/index.jsp) and includes versions 
compatible with Java, R or Gene Pattern. All GSEA analyses presented here were performed 
using the R GSEA implementation. 
DNAse Treatment and qRT-PCR  
Prior to cDNA conversion, RNA was treated with DNA-free DNase I kit (Ambion, 
AM1906). cDNA was produced by reverse transcription using 1 μg of DNA-free RNA in a 
35 μL reaction following TaqMan™ Reverse Transcription instructions (Applied Biosystems, 
N8080234). 20 ng/well of cDNA were used for the analysis performed in triplicate. 
Quantitative PCR was performed using the LightCycler® 480 SYBR green. Primer 
sequences are indicated below. Ct analysis was performed using LightCycler 480 software 290 
(Roche). All primers indicated below are in 5’  3’ direction. 
hEGFR Forward CCTGTCTGGAAGTACGCAG 
hEGFR Reverse GCGATGGACGGGATCTTAGG 
hERBB3 Forward CCGCTTGACTCAGCTCACC 
hERBB3 Reverse CACGATGTCCCTCCAGTCAAT 
hSLC25A30 Forward ACTGCTGAGTGCGGTACATT 
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hSLC25A30 Reverse GTCCTCTTGTCCCCTCTTGC 
hPPiA Forward ATGCTGGACCCAACACAAAT 
hPPiA Reverse TCTTTCACTTTGCCAAACACC 
Statistical Analyses 300 
All data are expressed as mean ± SEM. Statistical comparison was performed by Student’s t 
test using GraphPad Prism version 5.04. p ≤ 0.05 was considered statistically significant. The 
statistical significance of difference between groups is expressed by asterisks: *0.01 < p < 
0.05; **0.001 < p < 0.01; ***0.001 < p < 0.0001; ****p < 0.0001. 
Data availability 
All data generated or analyzed during this study are included in this published article and its 
supplementary information files. The original methylation and gene expression 
datasets generated during the current study are available in the GEO repository. 
Methylation data can be retrieved from GSE110184:   
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110184 token: ebatmokernwxzgl 310 
Expression data can be retrieved from GSE110153: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110153 token: gtajoqgurtkzjgx. 
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DNA-methylation patterns of breast cancer PDX resemble human primary breast tumors 
Hundreds of breast cancer PDX models have been established around the world (13), but 
whole-genome DNA-methylation analysis has not yet been reported. DNA-methylation status 
was analyzed for breast cancer PDX models and human tumors of origin when available. 
Methylation status was interrogated in 12 independent breast cancer PDX models previously 
generated (23–25) and four out of five human tumors of origin using the Infinium Human 320 
Methylation 450K and Infinium MethylationEPIC BeadChip Array from Illumina. The PDX 
models analysed include two luminal (IDB-03 and IDB-04), one ER+PR+HER2+ (IDB-05) 
and nine TNBC (IDB-01, IDB-02, IDB-09, HCI-001, BCM-4664, BCM-9161, VHIO-98, 
VHIO-127 and VHIO-270) all found to be sensitive to docetaxel (23¸ 27). Samples of 
residual disease after short term treatment with docetaxel for all sensitive TNBC PDX models 
and the matched PDX resistant variants (IDB-01R, IDB-02R, IDB-09R, VHIO-98R and 
VHIO-127R), generated after continuous docetaxel in vivo treatment were also included (23, 
27) (Supplementary Figure S1A). The Infinium Human Methylation 450K BeadChip array 
contains 485,512 probes covering 99% of RefSeq genes. The Infinium MethylationEPIC 
BeadChip array contains over 850,000 probes, which cover more than 90% of the sites on the 330 
Infinium Human Methylation 450K BeadChip array, plus more than 350,000 novel CpGs at 
regions identified as potential enhancers in the FANTOM5 project (31). A SNP analysis was 
performed to validate the identity of the PDX models and the human original tumors from 
which they derived when available (Supplementary Figure S1B). To minimize differences 
due to intratumor biological variability, two/three biological replicates per condition were 
included in the analyses. A first approach comparing whole-genome DNA-methylation using 
all CpG sites β-values between sensitive TNBC PDX models (Figure 1A) or between a 
TNBC and a luminal PDX model (Figure 1B) revealed a higher correlation between breast 
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cancer PDX models from the same subtype. Then, unsupervised analysis of most 
differentially methylated CpGs between breast cancer PDX models showed two major 340 
clusters that correlate with breast cancer subtypes: a cluster for TNBC PDX models and a 
cluster for non-TNBC PDX models (Figure 1C). Breast cancer PDX model IDB-03, which 
has lost estrogen and progesterone receptor expression (ER and PR, respectively), but 
expresses androgen receptor (17) (AR, data not shown) clusters with non-TNBC PDX models 
(Figure 1C). This result indicates that despite the loss of ER/PR in the breast cancer PDX 
model the global DNA-methylation profile is still luminal-like. Within the TNBC subgroup, 
segregation in two major DNA-methylation clusters is also observed (Figure 1C). One cluster 
contains the models IDB-02, VHIO-127 and BCM-9161, bearing BRCA1 germline mutations, 
as well as IDB-09 and HCI-001. A second cluster contains the non-BRCA1 mutated models 
IDB-01, VHIO-98, VHIO-270, and BCM-4664 (Figure 1C). Thus, segregation in two major 350 
DNA-methylation clusters based on hormone receptor expression observed in breast cancer 
patients (17) is maintained in our breast cancer PDX models, and two main TNBC 
methylations clusters, one of them enriched in BRCA1 mutated tumors, were found.   
Methylation patterns from breast cancer PDX models and human tumors of origin, TCGA 
breast cancer clinical samples (17) and breast cancer cell lines (BCCL) (28) were compared. 
A supervised cluster using the subtype methylation patterns extracted from TCGA revealed 
that each breast cancer PDX model and human tumor of origin was classified with human 
breast cancer samples from the same subtype (Figure 1D, Supplementary Table S1I). Ten out 
of the twelve breast cancer PDX models were mixed with TCGA breast tumors, while 
virtually all BCCLs classify separately from TCGA breast tumors (Figure 1D, chi square: 360 
25.9 p value < 0.00001). This result demonstrates that subtype-specific global DNA-
methylation from clinical breast cancer samples is conserved in breast cancer PDX models to 
a greater extent than in BCCLs. Distinctive DNA-methylation patterns for the different breast 
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cancer subtypes that correlate with clinical implications have been previously described in a 
collection of clinical samples containing TNBC (EpiBasal) and non-TNBC (EpiLum), cohort 
1 (32). A supervised hierarchical clustering of our breast cancer PDX models using these 
methylation signatures resulted in the classification of our TNBC (basal-like) PDX models as 
EpiBasal and the non-TNBC (luminal and triple-positive) PDX models as EpiLumB, 
including the IDB-03 model, despite the loss of ER/PR expression (Supplementary Figure 
S1C). This data supports the idea that the subtype-specific methylation patterns showed in 370 
primary breast tumors are maintained in breast cancer PDX models with clinical significance. 
Genome-wide DNA-methylation status from breast cancer PDX models and human 
mammary glands was compared (33,34), revealing a general hypomethylation pattern in 
breast cancer PDX models, while hypermethylation in some gene-specific CpG sites 
(Supplementary Figure S1D), which is also observed in original patient´s tumors. This result 
shows that variations in methylome between human mammary gland and human breast 
cancer are also conserved in breast cancer PDX models. Together these data reinforce the 
relevance of breast cancer PDX models to accelerate the translation into clinics of DNA-
methylation studies. 
 380 
Genome-wide DNA-methylation comparisons between paired sensitive and docetaxel 
resistant TNBC PDX models or residual disease evidences no global methylation changes 
As DNA-methylation changes in BCCLs have also been shown to contribute to taxane 
chemoresistance (10,35), we investigated whether changes in DNA-methylation patterns 
could be associated with docetaxel resistance in TNBC PDX models. We analysed DNA-
methylation patterns in paired sensitive and resistant (IDB-01S/R, IDB-02S/R, IDB-09S/R, 
VHIO-98S/R and VHIO-127S/R) and paired sensitive and residual disease (IDB-01S/RD, 
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IDB-02S/RD, IDB-09S/RD, VHIO-98S/RD, VHIO-127S/RD, VHIO-270S/RD, HCI-
001S/RD, BCM-4664S/RD, BCM-9161S/RD) TNBC PDX models.  
Unsupervised methylation cluster using the ten thousand most variable CpGs between all 390 
TNBC PDX models showed a clear separation between TNBC PDX models and no 
segregation based on docetaxel response (Figure 2A); however, within some models (VHIO-
98, VHIO-127, VHIO-270 and BCM-4664) some separation between sensitive, resistant and 
residual disease was observed (Figure 2A). CpG site methylation levels were highly 
correlated between sensitive and resistant tumors from the same TNBC PDX model, to a 
similar extent to that achieved when two sensitive tumor replicates from the same TNBC 
PDX model were compared (Figure 2B, Supplementary Table S1A). Principal component 
analyses also revealed a similar distribution of models, IDB-02 and VHIO-127 showing 
overlapping positions, BCM-9161, HCI-001 being the closer ones to IDB-02, whereas BCM-
4664, VHIO-98, VHIO-270 were closer to IDB-01S (Supplementary Figure S2A). IDB-01S 400 
and IDB-02S seem the most different ones according to this classification. This result 
suggests, on one hand, that methylation profile of residual disease is similarly close to that of 
resistant or sensitive tumors and, on the other hand, that most differences in DNA-
methylation are due to intratumor heterogeneity, ruling out global methylation changes 
during the emergence of docetaxel resistance.  
A comparison of whole genome DNA-methylation of sensitive and resistant groups based on 
CpG genomic region and CpG context revealed a genome-wide DNA-methylation increase in 
the promoter and CpG island context in the five chemoresistant TNBC PDX models 
(Supplementary Figure S2B-C). A similar genome-wide DNA-methylation increase was also 
observed in residual disease of most TNBC PDX models (Supplementary Figure S2B-C). 410 
To identify key DNA-methylation changes associated with response to docetaxel, 
differentially methylated CpGs between sensitive and resistant/residual disease groups from 
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all TNBC PDX models were extracted. Comparison of DNA-methylation at single base pair 
resolution using a minimum absolute methylation difference of 30% revealed high number of 
differentially methylated CpGs (hundreds to thousands) for some models (IDB-01, IDB-02, 
HCI-001, BCM-4664), and very few or none in others (BCM-9161, VHIO-98, VHIO-127) 
(Figure 2C, Supplementary Table S1B). Hypermethylation was found in some resistant 
TNBC PDX models (IDB-02R, IDB-09R, VHIO-98R) or residual disease (IDB-01RD, IDB-
02RD, BCM-4664 or VHIO-270), but hypomethylation was also observed (IDB-09RD, HCI-
001RD or VHIO-127RD) (Figure 2C).  420 
Some of the differentially methylated sites observed in the resistant models or residual 
disease were located in the promoter and CpG islands, but most of the differentially 
methylated sites in the resistant models were located in intergenic regions and open sea sites; 
whereas in residual disease they were found in the body and open sea sites (Supplementary 
Figure S3A-B). Comparison of differentially methylated CpGs between resistant TNBC PDX 
models revealed little overlap between them (Supplementary Figure S3C). Comparisons of 
residual disease were done separately for the two clusters, but little overlap was also observed 
(Supplementary Figure S3D).  
Analysis from Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways were conducted on DAVID bioinformatics web-based tool 430 
(https://david.ncifcrf.gov/). This analysis revealed alterations in common pathways between 
several resistant TNBC PDX models, such as calcium signalling, plasma membrane, cell 
junction and cell adhesion. In residual disease of the BRCA1-enriched cluster main common 
pathways included calcium ion binding, cytoskeleton, but also GTPase activity, PI3K activity 
or Ras signalling pathway (Supplementary Table S1C-D). 
Together these data suggest that emergence of chemoresistance to docetaxel in TNBC is not 
driven by global DNA-methylation changes nor single CpGs or genes between all TNBC 
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PDX models, as no common differentially methylated CpGs or genes between TNBC PDX 
models were found. However, within each model methylation changes were observed in the 
docetaxel resistant-derived TNBC PDX models and residual disease.  440 
 
DNA-methylation signature of resistance may predict response to chemotherapy in TNBC 
Next, we aimed to investigate the relevance of the DNA-methylation changes identified after 
short- or long-term treatment with docetaxel in our TNBC PDX models on basal-like clinical 
samples. We generated a methylation signature of docetaxel residual disease (RD1, 76 CpG) 
combining data from the 9 different pairs of S/RD TNBC PDX models and a methylation 
signature of docetaxel resistance (R1, 26 CpG) combining data from the 5 different pairs of 
S/R TNBC models analyzed (Supplementary Table S1E-F). Using the RD1 signature, TNBC 
PDX tumors do not longer cluster by model and two main clusters, one enriched in sensitive 
tumors and a second one enriched on residual disease were observed (Supplementary Figure 450 
S4A). Similarly, the R1 signature, segregate the PDX tumors in two clusters, one composed 
exclusively by resistant tumors, and a second one composed mainly by sensitive tumors 
(Supplementary Figure S4B). 
We then tested these signatures in two independent TNBC clinical cohorts where DNA-
methylation profiles were previously characterized (32,36). Cohort 1 contains samples from 
14 basal-like breast cancer patients (9 alive/responders, 5 exitus/non responders, with no 
treatment information available) (32), and cohort 2 contains 24 samples (all collected before 
treatment) of TNBC breast cancer patients, treated neoadjuvantly with taxanes, alone or in 
combination with anthracyclines (10 responders, 14 non-responders) (36). When we apply 
the R1 and RD1 signatures to these clinical cohorts, PDX and clinical samples remain in 460 
different clusters, and the responders from the clinical cohort 2 were not segregated 
(Supplementary Figure S4C-D). However, the R1 signature, but not RD1, classifies the 
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clinical samples from cohort 1 in 3 clusters: one of responders, one of non-responders and 
one enriched in responders (Supplementary Figure S4C-D). Then, we generated new 
signatures combining the clinical samples from cohort 1 with the S/RD and S/R PDX tumors 
(Supplementary Table S1G-H). In the resulting residual disease signature 2 (RD2, 478 CpG) 
there is a cluster composed mainly of residual disease PDX and a second cluster enriched in 
sensitive PDX and clinical responders (Supplementary Figure S5A). The same distribution is 
observed when the RD2 signature is applied to the clinical cohort 2 (Supplementary Figure 
S5B, chi square=9.31, p=0.002). The resulting resistant signature 2 (R2, 21 CpG) segregates 470 
clinical samples and PDX models in two clusters: one composed exclusively by resistant 
PDX/clinical non-responders and a second cluster divided in two subclusters, one enriched in 
resistant PDX/clinical non-responders and another enriched in sensitive PDX/clinical 
responders (Figure 3A). When this R2 signature is applied to the clinical cohort 2, for the first 
time all PDX and clinical samples are intermingled and subclassified by response to 
chemotherapy (Figure 3B). A cluster enriched in resistant PDX/clinical non-reponders and 
another enriched in sensitive PDX/clinical responders (chi square 17.8, p=0,00002) was 
shown. The mean methylation value of CpG from signature R2, but not RD2, could 
discriminate the clinical cohorts by chemotherapy response (Figure 3C and Supplementary 
Figure S5C). These results indicate that the R2 methylation signature may have predictive 480 
value to determine chemotherapy response to taxanes in TNBC patients.  
 
Poor association between gene-specific expression changes and DNA-methylation in 
TNBC PDX models 
Next, we selected models IDB-01 and IDB-02, representative of each TNBC cluster for 
further analyses. An unsupervised methylation cluster using the ten thousand most variable 
CpGs between tumors within each TNBC PDX model was performed. Separation between 
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sensitive and resistant samples for IDB-01 but not for the BRCA1-mutant IDB-02 was 
observed (Supplementary Figure S6A).  
It is well known the machinery and relationship between epigenetic changes, that includes 490 
methylation, and gene expression control in cancer (37). To investigate whether changes in 
gene expression between sensitive and resistant tumors were controlled by methylation, 
whole gene expression microarray analyses were performed. Three paired sensitive and 
resistant tumors from each TNBC PDX model using SurePrint G3 Human Gene Expression 
Microarray v2 platform from Agilent were analyzed. 
Pair-wise comparisons between sensitive and resistant IDB-01 and IDB-02 TNBC PDX 
models were performed using limma test, a complex ANOVA test that stabilizes the gene-
specific variance estimates (38), to identify strongly, differentially expressed genes (adj. p-
value < 0.05, fold change > |1.5|). A total of 702 genes in IDB-01, 304 downregulated and 
398 overexpressed, and 769 genes in IDB-02, 445 downregulated and 324 overexpressed 500 
(Figure 4A, Supplementary Figure S6B and Supplementary Table S2A), were identified as 
differentially expressed genes in chemoresistant compared to chemosensitive tumors. A set of 
35 genes, 7 in the same direction were identified as differentially expressed genes in common 
between both TNBC PDX models (Supplementary Figure S6B).  
GSEA revealed that resistant samples from IDB-01 model showed enrichment in pathways 
involved in extracellular matrix receptor interaction, focal adhesion and cell differentiation, 
being the EGFR pathway the most enriched (Supplementary Table S2B). Differential mRNA 
expression levels were found by qRT-PCR from EGFR (Supplementary Figure S6C) which 
was increased in docetaxel resistant tumors, whereas expression of another partner of the 
pathway, ERBB3, significantly decreased (Supplementary Figure S6C). No different 510 
expression of HER2 was found between sensitive and resistant IDB-01 PDX tumors (23). 
Although NRG1, a ligand of the EGF receptor family, was differentially methylated in the 
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gene body between sensitive and resistant tumors in both TNBC PDX models, its expression 
was below detection limits in both TNBC PDX models (Supplementary Table S1B and data 
not shown). In the case of IDB-02 TNBC PDX model, resistant tumors showed enrichment in 
genes associated to pathways of regulation of mitosis, replication and cell cycle according to 
the faster tumor growth found in chemoresistant tumors (23) (Supplementary Table S2B). 
GO and KEGG term analyses of gene expression data for IDB-01R PDX model highlighted 
extracellular space as significant (Supplementary Table S2C), but other pathways were 
deregulated (mitochondrion, amino acid transport, regulation of nitric oxide). In IDB-02R 520 
PDX model, the BRCA1-mutant model, expression changes were related mainly with immune 
response pathways, but also extracellular space (as in IDB-01R) and matrix organization and 
cell adhesion pathways were differentially regulated (Supplementary Table S2C).  
Correlations between promoter methylation (5’UTR, 1st exon, TSS200 and TSS1500 CpG 
gene regions) and global gene expression were extracted for IDB-01 and IDB-02 TNBC PDX 
models showing that there are mostly lineal positive correlations for both models [Figure 4B 
(blue lines), Supplementary Table S2D], indicating that global gene expression is not 
regulated by methylation. To characterize the significance of changes in DNA-methylation on 
gene expression during chemoresistance acquisition, a simple parametric test was applied to 
infer most differentially expressed genes between sensitive and resistant IDB-01 and IDB-02 530 
TNBC PDX models and correlate it with methylation. Analysis revealed that most 
differentially expressed genes (adj. p-value < 0.05, LogFC > |1.5|) were negatively correlated 
with methylation in IDB-01 TNBC PDX model but not in IDB-02 [Figure 4B (red lines) and 
Supplementary Table S2D].  
Conversely, the most differentially methylated CpGs in the promoter (5´UTR, 1st exon, 
TSS200 and TSS1500) (which are the most likely to affect expression), were selected and 
gene expression data for the corresponding transcripts was analyzed. As shown in Figure 4C 
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and Supplementary Table S2D, expected negative associations between methylation and 
expression were obtained for several transcripts in IDB-01, including: the top CpG more 
strongly hypomethylated in resistant tumors, the solute carrier SLC25A30, and the 540 
methyltransferase NNMT, which has been involved in anthracycline resistance in breast 
cancer (39), both with just one differentially methylated CpG at promoter and showing 
increased gene expression in IDB-01R PDX model (Figure 4C and Supplementary Table 
S2A). Several CpG were found hypermethylated in the promoter of PCCA, a mitochondrial 
enzyme propionyl-CoA carboxylase, and GJA1, a gap junction gene that forms intercellular 
channels, and accordingly the corresponding genes were downregulated in resistant IDB-01R 
tumors (Figure 4C and Supplementary Table S2A). Associations between methylation and 
expression were virtually absent for the BRCA1-mutant model IDB-02 (Figure 4C and 
Supplementary Table S2D). 
Pyrosequencing analysis confirmed that SLC25A30 promoter was differentially methylated, 550 
showing a hypomethylation pattern in IDB-01R (Figure 4D). As expected, analysis by qRT-
PCR showed higher mRNA expression levels of SLC25A30 in resistant IDB-01 TNBC PDX 
tumors (Figure 4E). Moreover, when we analyze methylation and expression data from same 
PDX tumor, a significant negative correlation was found (Figure 4F). SLC25A30 pertains to 
the family of solute carrier transporters and it appears to be consistently associated with 
ribosomal, mitochondrial and transport pathways (40) (Supplementary Table S2C). This data 
supports that SLC25A30 expression is controlled by promoter methylation and increased 
expression in resistant IDB-01 PDX could be associated to the emergence of 
chemoresistance. 
Taken together, these results do not show a general negative correlation between methylation 560 
and expression in basal conditions, but some genes could be controlled by methylation during 
the emergence of resistance, at least in the IDB-01R model. Some clinically relevant 
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pathways, as tyrosine kinase receptor pathway, have been unravelled using transcriptomic 
analyses of our paired sensitive and resistant TNBC PDX models, pointing out the reliability 
of breast cancer PDX models to study the emergence of resistance to chemotherapeutic drugs. 
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Breast cancer PDX have demonstrated to resemble the heterogeneity, drug response, invasive 
capabilities and growth rates of human cancers better than established BCCLs (12,13). In this 
work we found that breast cancer PDX maintain the genome-wide DNA-methylation patterns 570 
and the segregation in two major DNA-methylation clusters based on breast cancer subtype 
observed in breast cancer patients (17). Moreover, our TNBC PDX models clustered in two 
main groups, one of them including all BRCA1 mutant models. It is known that tumors with 
BRCA1 mutations show multiple copy number changes, being most of these gains and losses 
of genomic DNA a very characteristic pattern of the BRCA1 tumors (41). Differences in copy 
number changes induce methylation detection changes (42); then distinct methylation 
patterns detected could be associated to changes in copy number. Previous studies found 
three distinct methylation clusters associated with survival within the TNBC subtype (43).  
Global DNA-methylation profiles in PDX tumors are closer to primary tumors than those of 
BCCLs (44). Unlike in vitro cultured cell lines, which acquire accumulative epigenetic 580 
changes with passaging (45), breast cancer PDX models show a stable methylome even after 
continuous exposure to docetaxel. These results illustrate the superiority of breast cancer 
PDX models as compared to breast cancer cell lines as preclinical tools for methylation 
studies.  
The high similarity in DNA-methylation patterns between docetaxel sensitive and resistant-
derived or residual disease TNBC PDX models suggest that global DNA-methylation 
changes are not involved in the emergence of resistance to docetaxel in TNBC. However, a 
subset of differentially methylated CpGs, many of them in promoter regions, were found 
between sensitive and resistant-derived TNBC PDX models which could contribute to the 
emergence of resistance. Global DNA-methylation correlation values between sensitive and 590 
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residual disease or resistant tumors were similar, which supports that most global methylation 
changes observed were due to intratumor variability.  
The little overlap found in differential DNA-methylation and expression changes after 
docetaxel resistance emergence between TNBC models, reflects the high heterogeneity of the 
TNBC subtype, and the distinct biology of TNBC harbouring BRCA1 mutations. 
Despite the heterogeneity, the resistance signature obtained combining data of all paired 
sensitive and resistant TNBC PDX models with a small cohort of TNBC clinical samples, 
was able to segregate a second cohort of TNBC patients as responders or non-responders to 
taxane-based therapy.  
Global methylation and gene expression do not correlate in breast cancer PDX models, as 600 
observed in clinical samples (breast cancer, or other cancer types) (46), but for some genes, 
associations between differential CpG promoter methylation and gene expression were found, 
mainly in the IDB-01R model. The promoter of SLC25A30 is hypomethylated and the gene is 
overexpressed in IDB-01R PDX tumors, suggesting that methylation changes in SLC25A30 
may be associated to the emergence of docetaxel resistance in some TNBC, but further 
evidences are required.  
There are two main protein superfamilies of transporters: the ABC transporters and the SLC 
transporters (47). Some of these proteins, mainly ABC transporters have been associated with 
multidrug resistance in breast cancer (48). SLC25A30 pertains to the less studied SLC 
superfamily of transporters and it appears to be consistently associated with ribosomal, 610 
mitochondrial and transport pathways (34). Actually, mitochondrial dysfunction is a well-
known mechanism of cancer chemoresistance (49). 
Irrespectively of methylation, transcriptomic profiling revealed EGFR pathway as the most 
upregulated network during emergence of docetaxel resistance. Around 50% to 70% of 
TNBC/basal-like patients have shown to (over)express EGFR (50) and its expression has 
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been associated with poor prognosis (51). EGFR and HER2 pathways have been associated 
with poor response to chemotherapy (9,52) and clinical combinations of taxanes plus TKR 
inhibitors are under current study for the treatment of TNBC patients (53) which will be 
supported by our findings. 
We previously found that emergence of docetaxel resistance is accompanied by an increase in 620 
the CD49f+ population (23). Crosstalk and crossactivation between EGFR and CD49f has 
been described (54) and overexpression of both CD49f and EGFR genes has been associated 
with chemo and radioresistance in cancer (55) (56). New studies using EGFR inhibitors in 
combination with chemotherapy and other inhibitors, as dasatinib and mTOR/PI3K inhibitors 
show promising results (57). 
In conclusion, our findings demonstrate that breast cancer PDX are suitable models for 
methylation studies elucidating mechanisms of drug resistance related to methylation and 
gene expression. Although the emergence of resistance to docetaxel is not driven by global 
methylation changes, we identified key differentially methylated genes that can contribute to 
chemoresistance in TNBC. Moreover, gene expression pathways associate with 630 
chemoresistance in the clinics are also observed using TNBC PDX models.  
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Fig. 1. Global DNA-methylation patterns of breast cancer PDX resemble breast cancer 
human samples.  
A, B) Scatter plot of groupwise mean genome-wide DNA-methylation levels analyzed by 
GenomeStudio between two sensitive TNBC PDX models (A) or between a TNBC and a 
luminal PDX model (B). Correlations are indicated as r2. C) Unsupervised hierarchical 
clustering using 32.264 most differentially methylated CpGs between breast cancer PDX 
models. Methylation difference between at least one of the groups is equal or higher to 75% 
and p-value < 0.01. D) Supervised hierarchical clustering applying 743 selected CpGs that 840 
discriminate TNBC vs luminal subtype from TCGA breast cancer to BCCLs, breast cancer 
PDX models and human tumor samples of origin and TCGA clinical samples. Breast cancer 
PDX models are indicated. Chi-square and corresponding p-value indicating association 
between TCGA breast tumors and PDX models or BCCLs from the same subtype is indicated 
below. 
 
Fig. 2. Genome-wide DNA-methylation patterns between docetaxel sensitive, resistant 
and residual disease TNBC PDX models.  
A) Unsupervised hierarchical methylation clustering using the 10.000 most variable CpGs 
between TNBC PDX models including sensitive (untreated), residual disease and resistant 850 
tumors. All resistant tumors were collected at passage three of treatment, one week after last 
DTX treatment (23,27). Sensitive tumors were collected from a similar passage than resistant 
ones, to discriminate DTX specific changes with those related with serial passages. Residual 
disease was collected after two to eight doses of docetaxel when tumors were shrinking B) 
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Scatter plot of groupwise mean genome-wide DNA-methylation levels analyzed by 
GenomeStudio between sensitive and resistant pairs and between two different sensitive 
tumors from the same model. Correlations are indicated as r2. See also Supplementary Table 
S1A. C) Representation of differentially methylated sites indicating direction of change when 
comparing sensitive and resistant TNBC PDX tumors (top panel) or sensitive and residual 
disease (bottom panel). Total number of differentially methylated CpGs and genes for each 860 
TNBC PDX model are indicated. CpGs were selected by a methylation change higher than 
30% and a standard deviation lower than 0.05 between samples from the same group. The 
number of differentially methylated CpG from BCM-9161 RD (0 CpG) and VHIO-98RD (2 
CpG) was not enough to perform these analyses. 
Fig 3. DNA-methylation signatures as predictive tools for chemoresistance 
A, B) Supervised hierarchical clustering applying the R2 methylation signature: 21 CpGs that 
discriminate responders vs. non-responders (docetaxel sensitive vs resistant TNBC PDX (5 
pairs) and alive vs exitus breast cancer patients from cohort 1) in these PDX/cohort 1 (A) and 
adding cohort 2 (responders/non-responders) (B). Differentially Methylated Positions were 
found using minfi in statistical software R, with a p-value of 0.001. Chi-square and 870 
corresponding p-value indicating segregation between responder and non-responders is 
indicated. C) Association of R2 methylation signature (mean CpG methylation values) with 
chemotherapy response in both clinical cohorts. Mean values, box and whiskers (min to max) 
and t test p-values are shown. 
 
Fig. 4. Association between methylation and gene expression changes in sensitive and 
resistant TNBC PDX tumors.  
on July 24, 2019. © 2019 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 18, 2019; DOI: 10.1158/1541-7786.MCR-19-0040 
38 
 
A) Mean-centered gene expression of differentially expressed genes between sensitive and 
resistant tumors from IDB-01 and IDB-02 PDX model after limma test analysis. Genes are 
ordered vertically according to their expression. Overexpression (yellow) and 880 
underexpression (blue) are indicated. B) Density plot for correlation scores of methylation 
and gene expression for global, basal gene expression (blue line) and differentially expressed 
genes (red line) between sensitive and resistant IDB-01 PDX model. Number of genes used 
for correlations are indicated. C) Mean-centered methylation for each differentially promoter-
methylated CpG and corresponding mean-centered gene expression between sensitive and 
resistant tumors from IDB-01 and IDB-02 PDX model. Genes are ordered vertically 
according to their methylation change. D, E) Mean methylation levels of 4 CpG islands from 
SLC25A30 promoter (D) and SLC25A30 mRNA expression levels relative to PPiA (E) in 
sensitive and resistant tumors from IDB-01 measured by pyrosequencing and qRT-PCR, 
respectively. Mean, SEM and statistical significance are represented. F) Correlation between 890 
methylation and gene expression in the same IDB-01 PDX tumors. IDB-01S tumors are 
indicated in light blue while IDB-01R tumors are indicated in dark blue. R-square and p-
value indicating association between methylation and gene expression in IDB-01 TNBC PDX 
tumors are shown. 
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